Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852835 | 1.00 | MAPT (0.44) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL12233138 | 1.00 | MAPT (0.44) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL2308306 | 0.83 | MAPT (0.47) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL13447969 | 0.83 | MAPT (0.47) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL4778271 | 0.80 | MAPT (0.59) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL12893821 | 0.80 | MAPT (0.44) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| Trifluoroacetic Acid SCHEMBL27504505 | 0.80 | MAPT (0.44) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL10120333 | 0.80 | MAPT (0.44) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| Hydrochloric Acid SCHEMBL6559024 | 0.78 | MAPT (0.57) | MAPTKMT2ACYP2C19HIF1ACYP1A2 | |
| SCHEMBL888776 | 0.77 | CYP1A2 (0.42) | MAPTKMT2ACYP2C19HIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2020-08-27 | — | — | US | disclosed |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3357904-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180085306-A1 | THERAPEUTIC COMPOUNDS AND FORMULATIONS FOR INTRANASAL DELIVERY | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-03-29 | — | — | US | disclosed |
| EP-2167458-B1 | CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20170204079-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2017-07-20 | — | — | US | disclosed |
| US-9598355-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-9346798-B2 | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| CN-104761466-A | CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING EXPRESSION OF EXOGENOUS GENES VIA ECDYSONE RECEPTOR COMPLEX | INTREXON CORP | 2015-07-08 | — | — | CN | disclosed |
| US-20150099636-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORP (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150057271-A1 | DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2015-02-26 | — | — | US | disclosed |
| US-8884060-B2 | Process of preparing chiral diacylhydrazine ligands | INTREXON CORPORATION (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120316066-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-05-10 | — | — | US | disclosed |
| US-8076517-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| CN-101848887-A | Chiral diacylhydrazine ligands for modulating exogenous gene expression via ecdysone receptor complexes | INTREXON CORP | 2010-09-29 | — | — | CN | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163592-A1 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, CRYZ, TCF12 | MAPT 3998/4885KMT2A 1191/4885CYP2C19 3872/4885 |
| US-20150057271-A1 | DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS | SCN5A, KCNH1, KCNQ5 | MAPT 3220/4885KMT2A 1801/4885CYP2C19 1390/4885 |
| US-20170204079-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | MAPT 3998/4885KMT2A 1191/4885CYP2C19 3872/4885 |
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | MAPT 1941/4885KMT2A 2152/4885CYP2C19 11/4885 |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | MAPT 3998/4885KMT2A 1191/4885CYP2C19 3872/4885 |
| US-20120316066-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | MAPT 3998/4885KMT2A 1191/4885CYP2C19 3872/4885 |
| US-20150099636-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | MAPT 3998/4885KMT2A 1191/4885CYP2C19 3872/4885 |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, CRYZ, TCF12 | MAPT 3998/4885KMT2A 1191/4885CYP2C19 3872/4885 |
| US-20180085306-A1 | THERAPEUTIC COMPOUNDS AND FORMULATIONS FOR INTRANASAL DELIVERY | ACER2, TMPRSS15, ASAH2 | MAPT 2426/4885KMT2A 2808/4885CYP2C19 736/4885 |
| US-20120116090-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | MAPT 3998/4885KMT2A 1191/4885CYP2C19 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.